Nexalis Therapeutics Limited has released a press release.
Shareholder Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Nexalis Therapeutics Limited on 6ix
Earlier from Nexalis Therapeutics
- Issue of Securities Following General Meeting Approval
- Ethics Approval for Phase 2 Clinical Trial of IRX-211
- Sep24 Appendix 4C Cash Flow Report
- Sep24 Quarterly Activities Report
- $38.5m Funding to Fully Fund Clinical Development Plans
Later from Nexalis Therapeutics
- Dec24 Appendix 4C Cash Flow Report
- Dec24 Quarterly Activities Report
- Updated Dec24 Quarterly Activities Report
- Study Order Executed for Phase 2 BTcP Trial
- IRX-616a Study Order Executed to Commence Phase 1
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics